Conexeu Sciences develops a collagen-based extracellular matrix platform, CXU, designed as an injectable scaffold that supports natural tissue regeneration in applications ranging from wound care to medical aesthetics. The technology remains fluid at room temperature before forming a stable gel in the body and targets restoration of soft tissue lost to injury, aging or other causes.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -0.3 | — |
| Q2 2025 | 0 | — | -0.5 | — |
| Q1 2026 | 0 | — | -1.7 | — |
| Q2 2026 | 0 | — | -2.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Tailwind 2.0 Acquisition Corp. (TDWD), NervGen Pharma Corp. (NGEN), Imperial Petroleum Inc. (IMPP), National CineMedia, Inc. (NCMI), Melar Acquisition Corp. I (MACI), Twelve Seas Investment Company III (TWLV)